Kee Woo-Sung, Celltrion

Cell­tri­on to be­gin mass pro­duc­ing an­ti­body treat­ment be­fore get­ting ap­proval

In the race for some­thing — any­thing — to rein in the pan­dem­ic, Cell­tri­on says it will be­gin mass-pro­duc­ing its po­ten­tial Covid-19 an­ti­body treat­ment this month. The In­cheon, South Ko­rea-based com­pa­ny hopes to snag emer­gency ap­proval short­ly there­after.

The drug has gone through a Phase I tri­al with 32 vol­un­teers in South Ko­rea, and will be test­ed in 9 more pa­tients in an­oth­er Phase I study be­fore ad­vanc­ing to lat­er-stage tri­als, per a Reuters re­port. The biotech says it’s go­ing to reg­u­la­tors for emer­gency ap­proval soon — but could pro­duce about 1 mil­lion dos­es be­fore even get­ting the green light.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.